Eargo Inc. (Eargo), has agreed to pay $34.37 million to resolve allegations that it submitted, or caused the submission of, claims for hearing aid devices for reimbursement to the Federal Employees Health Benefits Program (FEHBP) that contained unsupported hearing loss diagnosis codes.
The FEHBP, administered by the U.S. Office of Personnel Management (OPM), is the largest employer-sponsored group health insurance program in the world. It provides health benefits through various health insurance carriers and covers over eight million federal employees, retirees, former employees, family members, and former spouses.
Certain FEHBP health insurance plans elect to offer a hearing aid benefit, which varies from plan to plan. FEHBP carriers that offer a hearing aid benefit require that claims for hearing aid devices include a hearing loss-related diagnosis code. These diagnosis codes must be supported by a hearing loss diagnosis, which is typically based on a hearing test performed by a health-care provider.
The United States alleged that, from January 1, 2017, through January 31, 2021, Eargo included unsupported hearing loss-related diagnosis codes on claims for hearing aid devices that Eargo submitted to the FEHBP and on invoices—called superbills—that Eargo provided to FEHBP beneficiaries to obtain reimbursement for such devices from the FEHBP.
The United States further alleged that between February 1, 2021, and September 22, 2021, Eargo continued to include these unsupported hearing loss-related diagnosis codes on claims and superbills—even after completing an internal review of its billing and coding practices in January 2021—resulting in Eargo knowingly submitting or causing the submission of false claims for payment to the FEHBP.
U.S. Department of Justice. (2022) Hearing aid company Eargo inc. agrees to pay $34.37 million to settle common law and false claims act allegations for unsupported diagnosis codes. Electronically published April 29.
The current FTC Guides state that “endorsers qualifications must in fact give the endorser the expertise that the endorser is represented as possessing with respect to the endorsement.” The proposed modification of an illustrative example in the Guides implies that an endorser of a hearing aid should not be referred to as “Doctor” as this…
Over-the-Counter (OTC) Hearing Aid Final Rule: Existing State Medical Clearance Requirements and “Prescription” Terminology
The Academy submitted a letter to the Federal Drug Administration (FDA) requesting clarification on two critical issues included in the final OTC rule to ensure the final rule can be implemented in an expeditious manner. Many state audiology licensing laws currently include a requirement that an individual receive medical clearance or sign a document waiving…
The Food and Drug Administration (FDA) released today the final rule, “Medical Devices; Ear, Nose, and Throat Devices; Establishing Over-the-Counter Hearing Aids.” The rule is available in the Federal Register, and the FDA has issued a press release. The effective date for the final rule is 60 days following publication in the Federal Register. The Academy’s OTC Task…